Ana Beatriz Serafim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Ana Beatriz Serafim has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Francesc Graus
Neuroimmunology Program, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Spain
3 shared publications - Josep Dalmau
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
3 shared publications - Lidia Sabater
Neuroimmunology Program, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Spain
3 shared publications - Mar Guasp
Neuroimmunology Program, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Spain
3 shared publications - Carles Gaig
Neurology Service, Sleep Centre, Hospital Clínic Barcelona, Universitat de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018‐ISCIII Barcelona Spain
2 shared publications - Raquel Ruiz-García
Department of Immunology, Biomedical Diagnostic Center, Hospital Clínic de Barcelona, Spain; and
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (5) , e200635
MOGAD-Like Encephalitic Syndromes Without MOG Antibodies in Children
Background and ObjectivesAlthough acute disseminated encephalomyelity (ADEM) can be myelin oligodendrocyte glycoprotein-IgG (MOG-IgG) positive or negative, it is unclear whether other MOG-antibody–...
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (5) , e200635
Open AccessMOGAD-Like Encephalitic Syndromes Without MOG Antibodies in Children
Background and ObjectivesAlthough acute disseminated encephalomyelity (ADEM) can be myelin oligodendrocyte glycoprotein-IgG (MOG-IgG) positive or negative, it is unclear whether other MOG-antibody–...
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (4) , e200600
Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease
Anti-IgLON5 disease is characterized by substantial clinical heterogeneity and variable outcomes. We investigated the associations of clinical features as well as serum neurofilament light chain (NfL), phosphorylated tau (p-tau), IgG4 levels, and the HLA-DRB110:01∼DQB105:01 haplotype with disease presentation and outcome. This is a retrospective observational study of patients with anti-IgLON5 disease diagnosed in our laboratory with adequate clinical information and follow-up. Neurologic disability was evaluated with the modified Rankin Scale (mRS) and the anti-IgLON5 composite score (ICS). Serum NfL and p-tau181 levels were measured using a commercial single-molecule array (Simoa) assay and IgG4 levels by flow cytometry. Associations between biomarkers and baseline clinical features were assessed using Spearman rank correlation and linear regression analyses. Prognostic variables were evaluated using binary logistic and Cox proportional hazards regression models. We included 78 patients (median age 66 years, 55% male). Higher serum NfL levels correlated with clinical severity at diagnosis, as measured with the mRS (r = 0.438; p = 0.002) and ICS (r = 0.30; p = 0.029). Patients with the HLA-DRB1*10:01∼DQB1*05:01 haplotype more frequently presented with the bulbar or sleep phenotypes (24/41; 58%) compared with those without the haplotype (4/28; 14%; p = <0.001). Sixty-six patients received immunotherapy, and 14 (21%) showed clinical improvement at the last follow-up. In the multivariate Cox regression model, the neuromuscular phenotype was the only independent predictor of good outcome (mRS: 0–3; HR: 10.8; 95% CI 2.48–47.1; p = 0.002). Among the 30 patients who died (42%), the strongest independent predictor of mortality was the bulbar phenotype (HR: 2.59; 95% CI 1.08–6.21; p = 0.033), while serum NfL levels showed a significant but limited association (HR: 1.02; 95% CI 1.00–1.04; p = 0.02). Serum NfL levels correlate with neurologic disability, whereas the bulbar phenotype was the main risk factor of mortality, indicating that these patients should be closely monitored and considered for early interventions (i.e., tracheostomy) that may modify an otherwise poor prognosis.
- 1 July 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (4) , e200600
Open AccessPrognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease
Anti-IgLON5 disease is characterized by substantial clinical heterogeneity and variable outcomes. We investigated the associations of clinical features as well as serum neurofilament light chain (NfL), phosphorylated tau (p-tau), IgG4 levels, and the HLA-DRB110:01∼DQB105:01 haplotype with disease presentation and outcome. This is a retrospective observational study of patients with anti-IgLON5 disease diagnosed in our laboratory with adequate clinical information and follow-up. Neurologic disability was evaluated with the modified Rankin Scale (mRS) and the anti-IgLON5 composite score (ICS). Serum NfL and p-tau181 levels were measured using a commercial single-molecule array (Simoa) assay and IgG4 levels by flow cytometry. Associations between biomarkers and baseline clinical features were assessed using Spearman rank correlation and linear regression analyses. Prognostic variables were evaluated using binary logistic and Cox proportional hazards regression models. We included 78 patients (median age 66 years, 55% male). Higher serum NfL levels correlated with clinical severity at diagnosis, as measured with the mRS (r = 0.438; p = 0.002) and ICS (r = 0.30; p = 0.029). Patients with the HLA-DRB1*10:01∼DQB1*05:01 haplotype more frequently presented with the bulbar or sleep phenotypes (24/41; 58%) compared with those without the haplotype (4/28; 14%; p = <0.001). Sixty-six patients received immunotherapy, and 14 (21%) showed clinical improvement at the last follow-up. In the multivariate Cox regression model, the neuromuscular phenotype was the only independent predictor of good outcome (mRS: 0–3; HR: 10.8; 95% CI 2.48–47.1; p = 0.002). Among the 30 patients who died (42%), the strongest independent predictor of mortality was the bulbar phenotype (HR: 2.59; 95% CI 1.08–6.21; p = 0.033), while serum NfL levels showed a significant but limited association (HR: 1.02; 95% CI 1.00–1.04; p = 0.02). Serum NfL levels correlate with neurologic disability, whereas the bulbar phenotype was the main risk factor of mortality, indicating that these patients should be closely monitored and considered for early interventions (i.e., tracheostomy) that may modify an otherwise poor prognosis.
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (4) , e200584
Human IgLON5 Antibodies Reduce Neuronal IgLON5 Clusters and Cause Motor Dysfunction in Mice
Background and ObjectivesAnti-IgLON5 disease is a progressive neurologic disorder characterized by sleep disturbances, gait instability, involuntary movements, and bulbar dysfunction. In long-stand...
- 1 July 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (4) , e200584
Open AccessHuman IgLON5 Antibodies Reduce Neuronal IgLON5 Clusters and Cause Motor Dysfunction in Mice
Background and ObjectivesAnti-IgLON5 disease is a progressive neurologic disorder characterized by sleep disturbances, gait instability, involuntary movements, and bulbar dysfunction. In long-stand...